Table 3.
Clinical Outcome Data Summary
| Overall Outcomes | Results, n (%) | ||
|---|---|---|---|
| Mortality | 39 (19.0) | ||
| Clinical success | 151 (73.7) | ||
| Microbiological cure | 145 (70.7) | ||
| Outcomes by infection type | |||
| Type (n)a | Microbiological Cure, n (%) | Clinical Success, n (%) | Mortality, n (%) |
| Bloodstream, primaryb (6) | 6 (100) | 6 (100) | 0 (0) |
| Bone/joint (16) | 13 (81.3) | 13 (81.3) | 0 (0) |
| Intra-abdominal (20) | 18 (90.0) | 15 (75.0) | 2 (10.0) |
| Pneumonia (121) | 69 (57.0) | 80 (66.1) | 31 (25.6) |
| VAP (58) | 31 (53.4) | 29 (50.0) | 22 (37.9) |
| Non-VAP (63) | 38 (60.3) | 51 (81.0) | 9 (14.2) |
| Wound (26) | 21 (80.8) | 21 (80.8) | 4 (15.4) |
| UTI (28) | 25 (89.3) | 25 (89.3) | 4 (14.3) |
Abbreviations: UTI, urinary tract infection; VAP, ventilator-associated pneumonia.
aSome patients had Pseudomonas isolated from multiple sites with multiple types of infection diagnosed; therefore, the total is greater than 205.
bPositive blood cultures for Pseudomonas with no other identified source of infection. In addition, 19 patients had secondary bacteremia. Of these 19, 13 (68%) had both microbiological cure and clinical success, and 7 (36.8%) died.